RU2491058C2 - Галеновый состав алискирена и гидрохлортиазида - Google Patents

Галеновый состав алискирена и гидрохлортиазида Download PDF

Info

Publication number
RU2491058C2
RU2491058C2 RU2009101971/15A RU2009101971A RU2491058C2 RU 2491058 C2 RU2491058 C2 RU 2491058C2 RU 2009101971/15 A RU2009101971/15 A RU 2009101971/15A RU 2009101971 A RU2009101971 A RU 2009101971A RU 2491058 C2 RU2491058 C2 RU 2491058C2
Authority
RU
Russia
Prior art keywords
dosage form
oral dosage
solid oral
amount
component
Prior art date
Application number
RU2009101971/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2009101971A (ru
Inventor
Маттиас ВИЛЛЬМАНН
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36803824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2491058(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2009101971A publication Critical patent/RU2009101971A/ru
Application granted granted Critical
Publication of RU2491058C2 publication Critical patent/RU2491058C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2009101971/15A 2006-06-23 2007-06-21 Галеновый состав алискирена и гидрохлортиазида RU2491058C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0612540.5A GB0612540D0 (en) 2006-06-23 2006-06-23 Galenical formulations of organic compounds
GB0612540.5 2006-06-23
PCT/EP2007/005476 WO2007147596A1 (en) 2006-06-23 2007-06-21 Galenical formulations of aliskiren and hydrochlorothiazide

Publications (2)

Publication Number Publication Date
RU2009101971A RU2009101971A (ru) 2010-07-27
RU2491058C2 true RU2491058C2 (ru) 2013-08-27

Family

ID=36803824

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009101971/15A RU2491058C2 (ru) 2006-06-23 2007-06-21 Галеновый состав алискирена и гидрохлортиазида

Country Status (26)

Country Link
US (1) US8618172B2 (enExample)
EP (3) EP2311439A1 (enExample)
JP (1) JP5362556B2 (enExample)
KR (1) KR101442272B1 (enExample)
CN (1) CN101472566A (enExample)
AR (1) AR061565A1 (enExample)
AU (1) AU2007263261B2 (enExample)
BR (1) BRPI0713338A2 (enExample)
CA (1) CA2654872A1 (enExample)
CL (1) CL2007001837A1 (enExample)
EC (1) ECSP088986A (enExample)
ES (1) ES2704979T3 (enExample)
GB (1) GB0612540D0 (enExample)
GT (1) GT200800297A (enExample)
IL (1) IL195425A (enExample)
MA (1) MA30527B1 (enExample)
MX (1) MX2008016533A (enExample)
MY (1) MY146779A (enExample)
NO (1) NO20090262L (enExample)
NZ (1) NZ572937A (enExample)
PE (2) PE20080373A1 (enExample)
RU (1) RU2491058C2 (enExample)
TN (1) TNSN08528A1 (enExample)
TW (1) TWI457137B (enExample)
WO (1) WO2007147596A1 (enExample)
ZA (1) ZA200809773B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100076996A (ko) * 2007-09-28 2010-07-06 노파르티스 아게 알리스키렌의 생약 제형
EP2143425A1 (de) * 2008-07-11 2010-01-13 Ratiopharm GmbH Direktverpresste Aliskiren-Tabletten
JP2010031006A (ja) * 2008-07-17 2010-02-12 Novartis Ag 有機化合物の使用
ES2365429B1 (es) 2010-03-05 2012-09-06 Universidad De Castilla De La Mancha Solucion para dialisis peritoneal
CN102626391B (zh) * 2012-04-19 2013-07-10 海南美兰史克制药有限公司 一种阿利克仑氢氯噻嗪药物组合物脂质体固体制剂
BR112015021002B8 (pt) * 2013-03-15 2023-03-28 Mallinckrodt Llc Forma de dosagem sólida farmacêutica compreendendo um ingrediente farmacêutico ativo

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006157B1 (ru) * 2002-07-05 2005-10-27 Софарма Ад Лекарственная форма силимарина и способ ее получения

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6010719A (en) 1997-09-16 2000-01-04 Universiteit Gent Freeze-dried disintegrating tablets
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
IS1935B (is) 2002-03-19 2004-06-16 Actavis Group Hf. Fósínópríl lyfjasamsetning
KR20100137026A (ko) * 2002-05-17 2010-12-29 노파르티스 아게 레닌 억제제, 칼슘 채널 차단제 및 이뇨제를 포함하는 약제학적 조성물
TW200538154A (en) 2004-02-17 2005-12-01 Novartis Ag Combination of organic compounds
MY144477A (en) 2004-03-17 2011-09-30 Novartis Ag Galenic formulations of organic compounds
WO2005118166A2 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
WO2006041763A1 (en) * 2004-10-04 2006-04-20 Novartis Ag Renin inhibitors for treating transplantation induced diseases
US8367105B2 (en) * 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
BRPI0609915A2 (pt) * 2005-04-27 2010-05-25 Novartis Ag métodos para tratar aterosclerose
RU2008119687A (ru) * 2005-10-21 2009-11-27 Новартис АГ (CH) Комбинации органических соединений

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006157B1 (ru) * 2002-07-05 2005-10-27 Софарма Ад Лекарственная форма силимарина и способ ее получения

Also Published As

Publication number Publication date
BRPI0713338A2 (pt) 2012-03-06
CL2007001837A1 (es) 2008-06-13
MY146779A (en) 2012-09-28
TW200808358A (en) 2008-02-16
NZ572937A (en) 2011-11-25
IL195425A (en) 2014-01-30
TWI457137B (zh) 2014-10-21
TNSN08528A1 (en) 2010-04-14
PE20080373A1 (es) 2008-06-06
EP2034968B1 (en) 2018-10-31
US8618172B2 (en) 2013-12-31
CN101472566A (zh) 2009-07-01
KR20090021353A (ko) 2009-03-03
US20090203679A1 (en) 2009-08-13
NO20090262L (no) 2009-01-19
ECSP088986A (es) 2009-01-30
AU2007263261B2 (en) 2011-07-14
EP3391878A1 (en) 2018-10-24
ZA200809773B (en) 2009-11-25
JP5362556B2 (ja) 2013-12-11
GB0612540D0 (en) 2006-08-02
EP2311439A1 (en) 2011-04-20
EP2034968A1 (en) 2009-03-18
PE20120990A1 (es) 2012-08-16
GT200800297A (es) 2009-03-09
KR101442272B1 (ko) 2014-09-22
RU2009101971A (ru) 2010-07-27
WO2007147596A1 (en) 2007-12-27
JP2009541239A (ja) 2009-11-26
MA30527B1 (fr) 2009-06-01
MX2008016533A (es) 2009-01-19
IL195425A0 (en) 2009-08-03
AR061565A1 (es) 2008-09-03
ES2704979T3 (es) 2019-03-21
CA2654872A1 (en) 2007-12-27
AU2007263261A1 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
RU2384328C2 (ru) Галеновы составы органических соединений
AU2007263261B2 (en) Galenical formulations of aliskiren and hydrochlorothiazide
US20110172309A1 (en) Galenic formulations of organic compounds
HK1152226A (en) Galenic formulations of organic compounds
MXPA06010482A (en) Galenic formulations of organic compounds
HK1147072A (en) Galenical formulations of aliskiren and hydrochlorothiazide
HK1152226B (en) Galenic formulations of organic compounds

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20160622